Fytexia

Fytexia is a life science company formed through the merger of ABbiotek Health, Fytexia, and Anzchem, specializing in the development of scientifically supported bioactive ingredients for dietary supplements and functional food applications. Headquartered in Vendres, France, near Montpellier, the company operates a global network of specialized manufacturing and research facilities, including a botanical blending facility in France, an enzyme production plant in Tarragona, Spain, a propolis extraction and spray-drying site in Corbetta, Italy, and a biotics blending facility in Etten-Leur, Netherlands. Commercial operations span North America, Europe, and Asia-Pacific, ensuring worldwide reach and customer proximity.

The company's ingredient portfolio is strategically focused on four core health areas: metabolic health, immune health, digestive health, and healthy ageing and vitality. For metabolic health, key branded ingredients include Sinetrol®, DNF-10®, Careflow®, Glyco680mg, and Oleactiv®, which support fat metabolism, glucose regulation, and circulatory function. In the immune health segment, Promunel® and Oxxynea® deliver standardized polyphenols and bioactive compounds to support natural defense mechanisms. Digestive health ingredients include Benegut® and adiDAO®, targeting microbiota balance, digestive comfort, and the gut-brain axis. For healthy ageing and vitality, the portfolio includes Fiit-ns®, MBP®, Bluenesse®, FWRD®, Mangoselect®, and Recoverben®, supporting bone strength, cognitive function, energy metabolism, and recovery.

Fytexia places a strong emphasis on rigorous scientific validation. Ingredients undergo comprehensive characterization, including profiling of active compounds, polyphenol content, chemical structure, bioavailability, pharmacokinetics, and strain genotyping. The company conducts gold-standard clinical research, including double-blind, randomized, placebo-controlled studies. For example, Care300®, a Mangifera indica L. fruit powder ingredient, has been studied in clinical trials demonstrating modulation of SIRT1, activation of AMPK by more than 50%, antioxidant effects through stimulation of SOD by more than 45%, anti-inflammatory effects, and significant improvements in fasting glucose, insulin sensitivity (HOMA-IR), glucose tolerance, and glycated hemoglobin.

The company's B2B business model is oriented toward enabling partners — including dietary supplement brands and functional food manufacturers — to develop effective, differentiated health products with measurable consumer benefits. Quality assurance is built into every stage of the ingredient lifecycle, from development through delivery. Fytexia operates exclusively in the business-to-business space, serving food and dietary supplement professionals globally.